Expanded Approval for ZYTIGA® for the Treatment of Castration-sensitive Prostate Cancer Approval BlogMedical CommunicationsOncology Updates Expanded Approval for ZYTIGA® for the Treatment of Castration-sensitive Prostate Cancer
Lutathera®, a New Treatment Option for Patients with Neuroendocrine Tumors Approval BlogMedical CommunicationsOncology Updates Lutathera®, a New Treatment Option for Patients with Neuroendocrine Tumors
Olaparib, the First PARP Inhibitor to Gain FDA Approval to Treat BRCA-mutant Breast Cancer Approval BlogMedical CommunicationsOncology Updates Olaparib, the First PARP Inhibitor to Gain FDA Approval to Treat BRCA-mutant Breast Cancer
Afatinib receives extended approval for frontline treatment of Patients with Non-resistant EGFR Mutation-positive NSCLC Approval BlogMedical CommunicationsOncology Updates Afatinib receives extended approval for frontline treatment of Patients with Non-resistant EGFR Mutation-positive NSCLC
Cadence expands its medical communication offerings through KOL Connect®, a comprehensive KOL relationship management solution FEATURED BLOGSFEATURED INSIGHTSMedical CommunicationsOncology Updates Cadence expands its medical communication offerings through KOL Connect®, a comprehensive KOL relationship management solution
What will be the impact of the ACA on cancer treatment? FEATURED INSIGHTSMedical CommunicationsOncology Updates What will be the impact of the ACA on cancer treatment?
